LIDDS is a Swedish drug delivery company that specializes in the innovative NanoZolid technology. This proprietary technology allows LIDDS to formulate drugs for local administration with a controlled and maintained release, lasting up to six months. With its versatile application, NanoZolid can be used for various drug classes, addressing multiple indication areas.

LIDDS offers the NanoZolid technology to partners and has also developed its own pipeline focused on oncology. This groundbreaking technology enables drug delivery locally and in high doses, administered over time with minimal side effects. The company has an extensive pipeline, with multiple projects in different stages of clinical development.

LIDDS is listed on Nasdaq First North Growth market and aims to create more effective and safer treatments by applying its patented drug delivery technology. With a strong pipeline and well-positioned drug delivery technology, LIDDS is an attractive partner for global partners seeking commercialization opportunities. Discover the potential of LIDDS in revolutionizing drug delivery and improving patient outcomes